Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer

BACKGROUND: A previous pivotal Phase III study (NO16966) demonstrated the benefit of the addition of bevacizumab (BV) to oxaliplatin-based regimens in metastatic colorectal cancer (MCRC). Our study evaluated the safety and efficacy of three oxaliplatin-based chemotherapy regimens (FOLFOX4 [intraveno...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohhara, Yoshihito, Suenaga, Mitsukuni, Matsusaka, Satoshi, Shinozaki, Eiji, Mizunuma, Nobuyuki, Yamaguchi, Toshiharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354450/
https://www.ncbi.nlm.nih.gov/pubmed/25767397
http://dx.doi.org/10.2147/OTT.S77190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354450/
https://www.ncbi.nlm.nih.gov/pubmed/25767397
http://dx.doi.org/10.2147/OTT.S77190

Ejemplares similares